Does Elevated Plasma Fibrinogen Increase the Risk of Coronary Heart Disease?: Evidence from a Meta-Analysis of Genetic Association Studies

Objective—The purpose of this study was to assess whether a genetic variant associated with higher fibrinogen levels is associated with increased coronary heart disease (CHD) risk, as a test of the causal influence of fibrinogen on CHD. Methods and Results—We performed a meta-analysis of case-control and prospective studies of the G-455→A and C-148→T β-fibrinogen promoter region variants, in relation to CHD risk. The 19 studies found included 12,393 cases and 21,649 controls. Fibrinogen levels were robustly related to the genetic variants (mean increase per allele, 0.117 g/L; 95% CI, 0.091–0.142 g/L). However, the genetic variants were unrelated to CHD risk (odds ratio per allele, 0.976; 95% CI, 0.916–1.040). The predicted causal odds ratio for a 1 g/L higher plasma fibrinogen level, given the genetic variant–fibrinogen and genetic variant–CHD associations, was 0.81 (95% CI, 0.46–1.40). Conclusions—Although imprecise, the predicted causal effect of fibrinogen on CHD is clearly different from the odds ratio of 1.8 (95% CI, 1.6–2.0) for an increase of 1 g/L derived from a meta-analysis of observational studies. This evidence suggests that lowering the fibrinogen level may not, in itself, reduce CHD risk.

[1]  Julian P T Higgins,et al.  Controlling the risk of spurious findings from meta‐regression , 2004, Statistics in medicine.

[2]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[3]  A. Marian,et al.  A variant of beta fibrinogen is a genetic risk factor for coronary artery disease and myocardial infarction. , 1996, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[4]  M. Mancini,et al.  Measuring plasma fibrinogen to predict stroke and myocardial infarction. , 1990, Arteriosclerosis.

[5]  P. Ridker,et al.  Mutation in the promoter region of the beta-fibrinogen gene and the risk of future myocardial infarction, stroke and venous thrombosis. , 2001, European heart journal.

[6]  A. Evans,et al.  β Fibrinogen Gene Polymorphisms Are Associated With Plasma Fibrinogen and Coronary Artery Disease in Patients With Myocardial Infarction , 1996 .

[7]  F. Rosendaal,et al.  Fibrinogen polymorphisms are not associated with the risk of myocardial infarction , 2000, British journal of haematology.

[8]  OdettePoirier,et al.  β Fibrinogen Gene Polymorphisms Are Associated With Plasma Fibrinogen and Coronary Artery Disease in Patients With Myocardial Infarction , 1996 .

[9]  A. Gardemann,et al.  Positive Association of the β Fibrinogen H1/H2 Gene Variation to Basal Fibrinogen Levels and to the Increase in Fibrinogen Concentration during Acute Phase Reaction but not to Coronary Artery Disease and Myocardial Infarction , 1997, Thrombosis and Haemostasis.

[10]  Sonia S Anand,et al.  Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. , 2003, JAMA.

[11]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[12]  J. Sterne,et al.  Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. , 2001, Journal of clinical epidemiology.

[13]  M. Margaglione,et al.  No Evidence of Association Between Prothrombotic Gene Polymorphisms and the Development of Acute Myocardial Infarction at a Young Age , 2003, Circulation.

[14]  R. Beaglehole,et al.  The search for new risk factors for coronary heart disease: occupational therapy for epidemiologists? , 2002, International journal of epidemiology.

[15]  S. Humphries,et al.  A common mutation (G-455--> A) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study. , 1997, Journal of Clinical Investigation.

[16]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[17]  D. Hackam,et al.  Emerging Risk Factors for Atherosclerotic Vascular Disease , 2003 .

[18]  A. Gardemann,et al.  Positive association of the beta fibrinogen H1/H2 gene variation to basal fibrinogen levels and to the increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction. , 1997, Thrombosis and haemostasis.

[19]  H. Izawa,et al.  Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. , 2002, The New England journal of medicine.

[20]  H. Völzke,et al.  Preoperative plasma fibrinogen levels predict mortality after coronary artery bypass grafting , 2003, Thrombosis and Haemostasis.

[21]  S. Thompson,et al.  An international and interregional comparison of haemostatic variables in the study of ischaemic heart disease. Report of a working group. , 1986, International journal of epidemiology.

[22]  D. Lawlor,et al.  Associations of fibrinogen and C-reactive protein with prevalent and incident coronary heart disease are attenuated by adjustment for confounding factors , 2005, Thrombosis and Haemostasis.

[23]  A. Hofman,et al.  Elevated plasma fibrinogen: cause or consequence of cardiovascular disease? , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[24]  S. Ebrahim,et al.  Mendelian randomization: prospects, potentials, and limitations. , 2004, International journal of epidemiology.

[25]  M. Marmot,et al.  Childhood social circumstances and psychosocial and behavioural factors as determinants of plasma fibrinogen , 1996, The Lancet.

[26]  S. Yusuf,et al.  Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. , 2001, Circulation.

[27]  P. McKeigue,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Problems of Reporting Genetic Associations with Complex Outcomes , 2022 .

[28]  J. Stamler Clofibrate and niacin in coronary heart disease. , 1975, JAMA.

[29]  W. Koenig Fibrinogen and coronary risk , 1999, Current cardiology reports.

[30]  G. Oh,et al.  Genetic factors associated with endothelial dysfunction affect the early onset of coronary artery disease in Korean males , 2001, Vascular medicine.

[31]  U. de Faire,et al.  The G‐455A polymorphism of the fibrinogen BΒ‐gene relates to plasma fibrinogen in male cases, but does not interact with environmental factors in causing myocardial infarction in either men or women , 2002, Journal of internal medicine.

[32]  M. Blombäck,et al.  The Role of β-Fibrinogen Genotype in Determining Plasma Fibrinogen Levels in Young Survivors of Myocardial Infarction and Healthy Controls from Sweden , 1993, Thrombosis and Haemostasis.

[33]  S. Ebrahim,et al.  'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.

[34]  K. Leander,et al.  The G-455A polymorphism of the fibrinogen Bbeta-gene relates to plasma fibrinogen in male cases, but does not interact with environmental factors in causing myocardial infarction in either men or women : Journal of Internal Medicine , 2002 .

[35]  G. Lowe,et al.  Fibrinogen, Factor VII and PAI-1 Genotypes and the Risk of Coronary and Peripheral Atherosclerosis: Edinburgh Artery Study , 1999, Thrombosis and Haemostasis.

[36]  V. Salomaa,et al.  Association of European population levels of thrombotic and inflammatory factors with risk of coronary heart disease: the MONICA Optional Haemostasis Study. , 2005, European heart journal.

[37]  G. Di Minno,et al.  Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[38]  Nilesh J Samani,et al.  Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study. , 2004, European heart journal.

[39]  G. Davey Smith,et al.  Fibrinogen, C-reactive protein and coronary heart disease: does Mendelian randomization suggest the associations are non-causal? , 2004, QJM : monthly journal of the Association of Physicians.

[40]  Sarah Parish,et al.  Plasma fibrinogen and fibrinogen genotypes in 4685 cases of myocardial infarction and in 6002 controls: Test of causality by "Mendelian randomisation" , 2000 .

[41]  R Peto,et al.  Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. , 1998, JAMA.

[42]  S. Yusuf,et al.  Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. , 2001, Circulation.

[43]  T. Meade,et al.  Bezafibrate in men with lower extremity arterial disease: randomised controlled trial , 2002, BMJ : British Medical Journal.

[44]  D. Arveiler,et al.  Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Etude Cas-Temoins sur l'Infarctus du Myocarde. , 1996, Circulation.

[45]  D. Cook,et al.  Ethnic differences in fibrinogen levels: the role of environmental factors and the beta-fibrinogen gene. , 2001, American journal of epidemiology.

[46]  G. Lip,et al.  Fibrinogen: biochemistry, epidemiology and determinants. , 2003, QJM : monthly journal of the Association of Physicians.

[47]  S. Brennan,et al.  Fibrinogen Bβ polymorphisms do not directly contribute to an altered in vitro clot structure in humans , 2003, Thrombosis and Haemostasis.

[48]  Eric Boerwinkle,et al.  β-Fibrinogen gene -455G/A polymorphism and coronary heart disease incidence: The Atherosclerosis Risk in Communities (ARIC) Study , 2001 .